MedTrace Logo

A Regulatory Requirement Post-Marketing Surveillance Study to Monitor the Safety and Efficacy of Twynsta (Telmisartan + Amlodipine SPC, q.d.) in Korean Hypertensive Patients Requiring Combination Therapy

NCT01243268 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 674

Last updated 2018-10-22

Study results available
· View outcomes & findings →

Summary

This is a prospective, observational, open-label, multi-center study, which will provide detailed information about the safety and efficacy of Twynsta tablets in Korean hypertensive patients requiring combination therapy. This will present a convenient treatment option for hypertension in Korean patients.

Conditions

Interventions

DRUG

Twynsta tablet

Telmisartan and Amlodipine T40/A5, T80/A5 and T40/A10

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-21
Primary Completion
2016-06-27
Completion
2016-08-18

Countries

  • South Korea

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01243268 on ClinicalTrials.gov